Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field studyExpect to ...

Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the drug's obesity potential. The biotech evaluated the candidate, dubbed HU6, ...

The latest update is out from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( ($HK:1349) ). Shanghai Fudan-Zhangjiang Bio-Pharmaceutical has ...

Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...

Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. "Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment," at 4:21 p.m. ET, ...

Memo Therapeutics is pressing ahead with its kidney transplant infection drug, advancing it to Phase III trials, despite falling short of its primary endpoint in a Phase II trial. The SAFE KIDNEY II ...

Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...

GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive ...